Navigation Links
IDEV Technologies Receives FDA Clearance for Its SUPERA VERITAS® 6 French Stent Delivery System
Date:11/10/2011

WEBSTER, Texas, Nov. 10, 2011 /PRNewswire/ -- IDEV Technologies, Incorporated (IDEV), today announced the FDA has granted 510(k) clearance for the company's 6 French (6Fr) SUPERA VERITAS Transhepatic Biliary Stent System.  The new lower profile system, approved for sale outside the U.S. earlier this year, is the latest enhancement to the delivery catheter utilized with the unique SUPERA stent, currently cleared in the U.S. for palliative treatment of biliary strictures produced by malignant neoplasms.

In addition to having a lower entry profile, the new 6Fr system is available in two catheter lengths, 80 cm and 120 cm, and offers even better efficiency and trackability.

"Feedback from our European customers confirms the new 6Fr system allows for improved ease of use, trackability and control of stent deployment," commented Christopher M. Owens, President and CEO of IDEV.  "As the global market continues to move toward smaller delivery sizes, we believe these regulatory clearances will provide an opportunity to accelerate market expansion and adoption of our technology.  We are pleased to now have this product available to our U.S. customers and patients."

Full commercial launch of the 6Fr SUPERA VERITAS Transhepatic Biliary Stent System is anticipated in January 2012.

About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology.  IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.

The SUPERA stent is currently indicated in the United States for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe, Canada, Australia and Hong Kong for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).

For more information please visit www.idevmd.com. Contact:

Donna LucchesiVice President Global MarketingIDEV Technologies, Incorporated(281) 525-2000
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Upgraded ACCF/ AHA/ SCAI Guidelines Reinforce Benefits of Volcanos Precision Guided Therapy Technologies
2. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
3. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
4. BioMarCare Technologies Ltd. Granted Access to Archived Samples in the Hadassah Medical Center
5. Medisafe 1 Technologies Pre-pays Additional 2 Convertible Promissory Notes Due in Full to Avoid Dilution to Shareholders
6. Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair
7. Micell Technologies Announces Presentation of Clinical Data at TCT 2011
8. China Medical Technologies to Announce Results for the Second Fiscal Quarter Ended September 30, 2011 on November 18, 2011
9. AquaLiv Technologies Subsidiary AquaLiv, Inc. Discusses Registration In Kenya Concerning Its HIV/AIDS Treatment
10. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
11. Connectyx Technologies to Host Teleconference on Third Quarter Financial Results on Tuesday November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... , Feb. 10, 2016 Mast ... developing novel, clinical-stage therapies for sickle cell disease and ... public offering of 29,090,910 units at a price to ... of one share of the Company,s common stock and ... common stock at an exercise price of $0.42 per ...
(Date:2/10/2016)... , Feb. 10, 2016 ALSP, Inc. announced ... MD as Consultant for Medical Affairs in preparation for its ... Michael Pierschbacher , PhD, CEO, stated, "We are pleased to ... look forward to working with an individual of such practical ... look forward to drawing deeply on his broad experience and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
(Date:2/10/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... its growing list of Partner Firms. S.S. Nesbitt is headquartered in Birmingham, ... and in between. , Harnessing the experience and insights of the agency’s team ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a definitive agreement ... laboratory service centers across the country. Launched in April of 2015, Apifiny is the ... prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and ...
(Date:2/10/2016)... ... 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves ... The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp explains ... is March 16, 2016. A free review copy is available to the media ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable ... find and select appointments via Everseat’s free mobile app. , The partnership gives ...
Breaking Medicine News(10 mins):